REMSleep Holdings, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsRemSleep Holdings is a Nevada sleep-apnea device company commercializing its DeltaWave nasal pillow CPAP interface after FDA clearance and commercial launch in early 2026.
What they do
RemSleep designs and sells the DeltaWave Nasal Pillow System, a patent-protected CPAP interface for obstructive sleep apnea. The company ceased selling CPAP machines in 2025 and now focuses solely on DeltaWave. It received FDA 510K clearance in January 2026 and launched the product commercially on February 24, 2026.
Revenue drivers
- DeltaWave Nasal Pillow System — Sole product line; generated $16,721 revenue in FY2025, with $12,707 cost of goods. No revenue in Q1 2026.
- CPAP machines (discontinued) — Generated $117,185 revenue in FY2024; stopped selling in 2025.
Recent performance
FY2025 revenue was $16,721, down from $117,185 in 2024, due to product transition. Net loss widened to $3.0M from $1.1M, driven by $2.16M non-cash stock compensation to former CEO and COO. Q1 2026 revenue was zero; total assets $223,512, liabilities $346,063, and shareholder equity negative $122,551 as of March 31, 2026.
Strategy
Management aims to establish DeltaWave as a rescue mask for CPAP-failure patients, leveraging its patented Direct Airflow Technology. They are building a nationwide sales team and negotiating with a hospital distributor to enter institutional settings. They plan to capture 10% of the OSA market within 24 months and conduct a clinical user preference trial.
Risks
- Minimal revenue history — Only $16,721 revenue in 2025 and zero in Q1 2026; no proven commercial traction.
- Severe negative equity — Shareholder equity is -$122,551 as of March 31, 2026, and cash is only $87,953.
- Dependence on former CEO compensation — Large non-cash compensation expenses (e.g., $2.16M in 2025) may indicate governance and control issues.
- Competitive market — Larger, better-capitalized competitors dominate CPAP accessory market, limiting pricing power.
Outlook
Management expects sales to ramp in Q2 2026 as the DME onboarding cycle completes (average 3 months). They are negotiating with a key hospital distributor to launch DeltaWave in U.S. hospitals. They also hope to start a clinical user preference trial later this year.